Generic Drugs Market in Japan 2015-2019

A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.

This report analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.

Covered in this Report

The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the following segments:

• Generic Prescription Medicines

• Super Generics

• Biosimilars

The Generic Drugs market in Japan 2015-2019 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

• Meiji Seika Pharma

• Nichi-Iko Pharmaceutical

• Nipro Pharma

• Sawai Pharmaceuticals

• Teva Pharmaceutical Industries

• Towa Pharmaceutical

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview...